Heart Failure Management with ACEIs, ARBs, Beta-Blockers, Diuretics, and Digoxin

Heart failure (HF) is a complex clinical syndrome characterized by the heart’s inability to pump blood sufficiently to meet the metabolic demands of the body. In recent years, major therapeutic advances have significantly improved outcomes for patients with certain types of heart failure. This article provides an overview of the pharmacological management of heart failure, focusing on Heart Failure with Reduced Ejection Fraction (HFrEF) and briefly addressing Heart Failure with Preserved Ejection Fraction (HFpEF).

1. Overview of Heart Failure

1.1 Classifications of Heart Failure

Heart Failure with Reduced Ejection Fraction (HFrEF)
- Definition: Left Ventricular Ejection Fraction (LVEF) < 40%
- Pathophysiology: Systolic dysfunction; the heart muscle is weakened, resulting in inadequate pump function.
Heart Failure with Preserved Ejection Fraction (HFpEF)
- Definition: LVEF ≥ 50%
- Pathophysiology: Diastolic dysfunction; the ventricular walls are stiff and noncompliant, leading to impaired filling.

Between these two ends of the spectrum are patients sometimes classified as HFmrEF (Heart Failure with mildly reduced EF, 41–49%)—but the main management focus has historically been on HFrEF, where robust evidence-based medications have been shown to improve survival.

1.2 Clinical Presentation and Physical Examination

Symptoms: Dyspnea (on exertion or at rest), orthopnea, paroxysmal nocturnal dyspnea, fatigue, and reduced exercise tolerance.
Signs:
- Jugular Venous Distension (JVD): Sign of elevated right-sided pressures.
- Peripheral Edema: Common in advanced or right-sided failure.
- Pulmonary Rales (Crackles): Indicative of pulmonary congestion in left-sided failure.
- Gallop Rhythms:
  - S3: Often present in HFrEF (due to volume overload and dilated ventricle).
  - S4: Often present in HFpEF (due to stiff ventricle).

2. Pharmacological Management of HFrEF

Evidence-based therapy for HFrEF aims to:

Improve symptoms and quality of life.
Decrease hospitalizations.
Prolong survival.

The cornerstone therapies for HFrEF target neurohormonal pathways (e.g., renin-angiotensin-aldosterone system [RAAS], sympathetic nervous system) and the body’s fluid balance.

2.1 Angiotensin-Converting Enzyme Inhibitors (ACEIs)

Mechanism: Block the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. This lowers afterload and preload, slowing disease progression and improving survival.

Common Examples and Starting Doses
- Lisinopril: Start 2.5–5 mg once daily; target 20–40 mg once daily
- Enalapril: Start 2.5 mg twice daily; target 10–20 mg twice daily
- Ramipril: Start 1.25–2.5 mg once daily; target 10 mg once daily
Monitoring & Side Effects
- Monitor: Renal function (serum creatinine), serum potassium, and blood pressure.
- Side Effects: Cough (due to bradykinin), hyperkalemia, risk of acute kidney injury, and angioedema (rare).

2.2 Angiotensin II Receptor Blockers (ARBs)

Mechanism: Block the angiotensin II type 1 (AT1) receptor, resulting in effects similar to ACEIs but without the accumulation of bradykinin.

Use: Primarily in patients intolerant to ACEIs (e.g., due to cough).
Common Examples and Starting Doses
- Losartan: Start 25–50 mg once daily; target 50–150 mg once daily
- Valsartan: Start 40 mg twice daily; target 160 mg twice daily
- Candesartan: Start 4–8 mg once daily; target 32 mg once daily
Monitoring & Side Effects
- Monitor: Renal function, potassium, and blood pressure.
- Side Effects: Hyperkalemia, hypotension, and renal impairment (similar to ACEIs, but no cough).

2.3 Angiotensin Receptor–Neprilysin Inhibitor (ARNI)

Mechanism: Combines an ARB (valsartan) with sacubitril, a neprilysin inhibitor. Neprilysin breaks down natriuretic peptides, so inhibiting it increases beneficial natriuretic peptide levels, promoting vasodilation and natriuresis.

Sacubitril/Valsartan (Entresto)
- Starting Dose: 49/51 mg twice daily
- Target Dose: 97/103 mg twice daily (after 2–4 weeks if tolerated)
Key Consideration: Patients must discontinue ACEIs at least 36 hours before starting ARNI to reduce the risk of angioedema.
Monitoring & Side Effects: Similar to ACEIs/ARBs (BP, renal function, potassium).

2.4 Beta-Blockers

Mechanism: Block the effects of catecholamines (e.g., norepinephrine, epinephrine), reducing heart rate and myocardial oxygen demand, allowing the heart to remodel more favorably over time.

Evidence-Based Beta-Blockers in HF
- Carvedilol: Start 3.125 mg twice daily; target 25–50 mg twice daily
- Metoprolol Succinate (Extended-Release): Start 12.5–25 mg once daily; target 200 mg once daily
- Bisoprolol: Start 1.25 mg once daily; target 10 mg once daily
Initiation & Titration
- Start low and go slow (increase dose every 2 weeks if stable).
- Avoid starting or increasing doses during acute decompensation.
Monitoring & Side Effects
- Monitor: Heart rate, blood pressure, and signs of congestion.
- Side Effects: Bradycardia, hypotension, fatigue, potential transient worsening of HF when first initiating.

2.5 Mineralocorticoid Receptor Antagonists (MRAs)

Mechanism: Block aldosterone receptors, reducing sodium and water retention and preventing myocardial fibrosis and remodeling.

Common Examples and Doses
- Spironolactone: Start 12.5–25 mg once daily; target 25–50 mg once daily
- Eplerenone: Start 25 mg once daily; target 50 mg once daily
Monitoring & Side Effects
- Monitor: Serum potassium, renal function (especially in older or diabetic patients).
- Side Effects: Hyperkalemia, gynecomastia (less with eplerenone), renal dysfunction.

2.6 SGLT2 Inhibitors

Originally developed for type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown mortality and hospitalization benefits in HFrEF (and more recently in HFpEF).

Common Examples
- Dapagliflozin: 10 mg once daily
- Empagliflozin: 10 mg once daily
Mechanism
- Promote glycosuria (if hyperglycemic) and natriuresis, reduce plasma volume, and have favorable effects on cardiac remodeling.
Monitoring & Side Effects
- Monitor: Renal function, volume status.
- Side Effects: Genitourinary infections, possible euglycemic ketoacidosis in rare cases.

2.7 Diuretics

Mechanism: Reduce fluid overload (preload), relieving symptoms such as pulmonary and peripheral edema. Although they do not directly improve survival, diuretics are essential for symptom management.

Loop Diuretics (first-line diuretics in HF)
- Furosemide: 20–40 mg once daily or BID; can titrate to higher doses based on fluid status
- Torsemide: 10–20 mg once daily; more predictable absorption than furosemide
- Bumetanide: 0.5–1 mg once daily or BID; potent with good bioavailability
Thiazide Diuretics (often adjuncts for resistant edema)
- Hydrochlorothiazide: 25–50 mg once daily
Monitoring & Side Effects
- Monitor: Electrolytes (especially potassium and magnesium), renal function, daily weights, and blood pressure.
- Side Effects: Hypokalemia, hypotension, volume depletion, and potential worsening of renal function.

2.8 Hydralazine and Isosorbide Dinitrate

Mechanism:

Hydralazine: Arterial dilator → reduces afterload.
Isosorbide Dinitrate: Venodilator → reduces preload.
Indications
- Particularly beneficial in African American patients with HFrEF in addition to standard therapy.
- Alternative for patients who cannot tolerate ACEIs/ARBs.
Typical Doses
- Hydralazine: Start 25 mg TID; target 75–100 mg TID
- Isosorbide Dinitrate: Start 20 mg TID; target 40 mg TID
Monitoring & Side Effects
- Side Effects: Headache, hypotension, reflex tachycardia, drug-induced lupus-like syndrome (with hydralazine).

2.9 Ivabradine

Mechanism: Selectively inhibits the funny current (If) in the sinoatrial node, reducing heart rate without affecting contractility.

Indications: Patients with HFrEF (LVEF ≤ 35%) in sinus rhythm with a resting HR ≥ 70 bpm despite maximally tolerated beta-blockers or in cases of beta-blocker intolerance.
Doses
- Start 5 mg twice daily; can adjust to 7.5 mg twice daily if heart rate remains above 60 bpm and there are no limiting side effects.
Monitoring & Side Effects
- Side Effects: Bradycardia, phosphenes (visual brightness), and possible atrial fibrillation.
- Monitor: Heart rate, cardiac rhythm, blood pressure.

2.10 Digoxin

Mechanism: Inhibits the Na⁺/K⁺-ATPase pump, leading to modest inotropic support (increased contractility). Also helps control ventricular rate in patients with atrial fibrillation.

Doses
- Generally 0.125–0.25 mg once daily. Adjust for renal function and patient weight.
Monitoring & Side Effects
- Therapeutic range: ~0.5–0.9 ng/mL in HF.
- Toxicity: Nausea, vomiting, visual disturbances (yellow halos), cardiac arrhythmias.
- Monitoring: Renal function, potassium (hypokalemia predisposes to toxicity).

3. Management of HFpEF

While no therapies definitively improve mortality in HFpEF to the extent seen in HFrEF, treatment focuses on:

Volume Management: Use of diuretics to relieve symptoms of congestion.
Blood Pressure Control: ACEIs, ARBs, or other antihypertensives as needed.
Heart Rate Control (if atrial fibrillation is present): Beta-blockers, non-dihydropyridine calcium channel blockers.
SGLT2 Inhibitors: Emerging evidence suggests a role for SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) in improving outcomes in HFpEF.

4. General Clinical Considerations

Start Low and Go Slow: Particularly for ACEIs, ARBs, beta-blockers, and MRAs. This minimizes the risk of hypotension and other side effects.
Monitor Renal Function and Electrolytes: Renal perfusion can change as afterload/preload reduces. Watch for rises in serum creatinine and changes in potassium.
Patient Education:
- Daily weight monitoring to detect early fluid retention.
- Dietary sodium restriction (usually < 2 g/day).
- Fluid restriction in certain cases (e.g., severe volume overload or hyponatremia).
Comorbidity Management: Address ischemic heart disease, valvular problems, hypertension, arrhythmias (especially atrial fibrillation), and diabetes mellitus.

5. Putting It All Together: A Typical HFrEF Strategy

Initiate RAAS Inhibition: Start an ACEI (or ARB if intolerant). Transition to ARNI (Sacubitril/Valsartan) in eligible patients with persistent symptoms or as per guidelines.
Add a Beta-Blocker: Once the patient is stable, start with a low dose and titrate slowly.
Add a Diuretic: If there is evidence of fluid overload. Adjust dose according to symptoms and daily weights.
Add a Mineralocorticoid Receptor Antagonist: If EF ≤ 35% and no contraindications (e.g., significant renal dysfunction or hyperkalemia).
Consider SGLT2 Inhibitors: Recommended for additional mortality and hospitalization benefits in HFrEF.
Add Other Agents as Appropriate:
- Hydralazine/Nitrates: Particularly in African American patients or those intolerant to ACEIs/ARBs.
- Ivabradine: If heart rate remains ≥ 70 bpm on maximally tolerated beta-blockers (and in sinus rhythm).
- Digoxin: For rate control in atrial fibrillation or when additional symptom control is required.

6. Conclusion

Heart Failure management requires a systematic approach:

Optimize foundational treatments (RAAS inhibitors, beta-blockers, diuretics, MRAs, and SGLT2 inhibitors).
Individualize therapy based on comorbidities, tolerance, and side effects.
Monitor patients closely for changes in volume status, renal function, and electrolytes.

By understanding the mechanism, dosing, and monitoring of these key drug classes, medical students can lay a strong foundation for providing evidence-based care to patients with heart failure. Early identification of decompensation and regular follow-up are critical for improving clinical outcomes and patients’ quality of life.

Key Takeaways

HFrEF: Multiple drug classes (ACEIs/ARBs/ARNI, beta-blockers, MRAs, SGLT2 inhibitors) have proven mortality benefits.
HFpEF: Focus on managing comorbidities, controlling volume overload, and optimizing blood pressure; SGLT2 inhibitors are showing promise.
Diuretics: Essential for symptom control but do not alter mortality.
Monitoring: Renal function, electrolytes, blood pressure, heart rate, and daily weights.
Patient Education: Critical for adherence, early detection of fluid retention, and successful long-term management.